knowledge -WSS

knowledge

author：hotspot 2025-10-01 03:41:03 - browse：1843

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： The future of health care in the House

WSS

Bristol Myers buys into radiopharmaceuticals with RayzeBio

CRISPR gene editing developments we’re watching in 2024

Senate panel eyes new effort on drug shortages

Phenylephrine and the overlooked value of the placebo effect

Prime Medicine, Myeloid Therapeutics clash over genome

SEC charges former device maker CEO with $41 million fraud

focus

knowledge

entertainment

Drug repurposing or repositioning? The language matters

What STAT readers think about the FDA and patient advocacy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AI can decode, harness the power of the humane immune system

Heart attack and stroke risk calculators need revising

Why age limits for politicians are a terrible idea

Trump demands the U.S. pay no more for drugs than other countries … again

FDA authorizes Novavax’s updated Covid

Anesthesiologist group: stop taking Ozempic before surgery

Carvykti CAR

hotspot

Virtual care provider acquires bankrupt Pear's prescription apps

Colorectal cancer study finds potential in overlooked immune cell

Why health care costs have stayed mostly flat since 2010

Why health records don't always know when patients are dead

Was Amgen transparent enough on FDA's concern on cancer drug?

VC firm General Catalyst wants to buy a health system

knowledge

leisure time

entertainment

focus